IRIS Accounts Production v24.3.2.46 12088745 Board of Directors 1.8.23 31.7.24 31.7.24 0 false true false false true false ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh120887452023-07-31120887452024-07-31120887452023-08-012024-07-31120887452022-07-31120887452022-08-012023-07-31120887452023-07-3112088745ns15:EnglandWales2023-08-012024-07-3112088745ns14:PoundSterling2023-08-012024-07-3112088745ns10:Director12023-08-012024-07-3112088745ns10:PrivateLimitedCompanyLtd2023-08-012024-07-3112088745ns10:SmallEntities2023-08-012024-07-3112088745ns10:AuditExempt-NoAccountantsReport2023-08-012024-07-3112088745ns10:SmallCompaniesRegimeForDirectorsReport2023-08-012024-07-3112088745ns10:SmallCompaniesRegimeForAccounts2023-08-012024-07-3112088745ns10:FullAccounts2023-08-012024-07-3112088745ns10:OrdinaryShareClass12023-08-012024-07-3112088745ns10:Director22023-08-012024-07-3112088745ns10:CompanySecretary12023-08-012024-07-3112088745ns10:RegisteredOffice2023-08-012024-07-3112088745ns5:CurrentFinancialInstruments2024-07-3112088745ns5:CurrentFinancialInstruments2023-07-3112088745ns5:Non-currentFinancialInstruments2024-07-3112088745ns5:Non-currentFinancialInstruments2023-07-3112088745ns5:ShareCapital2024-07-3112088745ns5:ShareCapital2023-07-3112088745ns5:RetainedEarningsAccumulatedLosses2024-07-3112088745ns5:RetainedEarningsAccumulatedLosses2023-07-3112088745ns5:PlantMachinery2023-08-012024-07-3112088745ns5:PlantMachinery2023-07-3112088745ns5:ComputerEquipment2023-07-3112088745ns5:ComputerEquipment2023-08-012024-07-3112088745ns5:PlantMachinery2024-07-3112088745ns5:ComputerEquipment2024-07-3112088745ns5:PlantMachinery2023-07-3112088745ns5:ComputerEquipment2023-07-3112088745ns5:BetweenOneTwoYearsns5:Non-currentFinancialInstruments2024-07-3112088745ns5:BetweenOneTwoYearsns5:Non-currentFinancialInstruments2023-07-3112088745ns10:OrdinaryShareClass12024-07-3112088745ns5:RetainedEarningsAccumulatedLosses2023-07-3112088745ns5:RetainedEarningsAccumulatedLosses2023-08-012024-07-31
















Unaudited Financial Statements for the Year Ended 31 July 2024

for

Medlok Medical Limited

Medlok Medical Limited (Registered number: 12088745)






Contents of the Financial Statements
for the Year Ended 31 July 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


Medlok Medical Limited

Company Information
for the Year Ended 31 July 2024







DIRECTORS: K G Harrison
Mrs L A Harrison





SECRETARY:





REGISTERED OFFICE: Unity House
Medlock Street
Oldham
OL1 3HS





REGISTERED NUMBER: 12088745 (England and Wales)





ACCOUNTANTS: Peter Upton
Bridge House
2 Bridge Avenue
Maidenhead
Berkshire
SL6 1RR

Medlok Medical Limited (Registered number: 12088745)

Balance Sheet
31 July 2024

31.7.24 31.7.23
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 1,832 2,749

CURRENT ASSETS
Cash at bank 36 79

CREDITORS
Amounts falling due within one year 5 77,894 67,984
NET CURRENT LIABILITIES (77,858 ) (67,905 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(76,026

)

(65,156

)

CREDITORS
Amounts falling due after more than one year 6 7,490 15,589
NET LIABILITIES (83,516 ) (80,745 )

CAPITAL AND RESERVES
Called up share capital 7 2 2
Retained earnings 8 (83,518 ) (80,747 )
SHAREHOLDERS' FUNDS (83,516 ) (80,745 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 July 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 July 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 8 April 2025 and were signed on its behalf by:





K G Harrison - Director


Medlok Medical Limited (Registered number: 12088745)

Notes to the Financial Statements
for the Year Ended 31 July 2024

1. STATUTORY INFORMATION

Medlok Medical Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 25% on reducing balance

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2023 - 2 ).

4. TANGIBLE FIXED ASSETS
Office &
Plant and sundry
machinery equipment Totals
£    £    £   
COST
At 1 August 2023
and 31 July 2024 7,984 706 8,690
DEPRECIATION
At 1 August 2023 5,458 483 5,941
Charge for year 842 75 917
At 31 July 2024 6,300 558 6,858
NET BOOK VALUE
At 31 July 2024 1,684 148 1,832
At 31 July 2023 2,526 223 2,749

Medlok Medical Limited (Registered number: 12088745)

Notes to the Financial Statements - continued
for the Year Ended 31 July 2024

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.7.24 31.7.23
£    £   
Bank loans and overdrafts 8,614 8,614
Social security and other taxes - 37
Directors' current accounts 68,440 58,833
Accrued expenses 840 500
77,894 67,984

6. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
31.7.24 31.7.23
£    £   
Bank loans - 1-2 years 7,490 15,589

7. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31.7.24 31.7.23
value: £    £   
2 ordinary £1 2 2

8. RESERVES
Retained
earnings
£   

At 1 August 2023 (80,747 )
Deficit for the year (2,771 )
At 31 July 2024 (83,518 )